Clinical trial
Erlotinib and Green Tea Extract (Polyphenon® E) in Preventing Cancer Recurrence…
NCT00088946 · Jonsson Comprehensive Cancer Center, Other · Completed
Key facts
| NCT number | NCT00088946 |
|---|---|
| Title | Erlotinib and Green Tea Extract (Polyphenon® E) in Preventing Cancer Recurrence in Former Smokers Who Have Undergone Surgery for Bladder Cancer |
| Official title | Parallel, Randomized, Double-Blind, Placebo Controlled Phase II Adjuvant Studies of Erlotinib and Polyphenon E to Prevent the Recurrence and Progression of Tobacco-Related, Superficial Bladder Cancer |
| Lead sponsor | Jonsson Comprehensive Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Bladder Cancer |
| Intervention type | Dietary Supplement, Drug, Other |
| Interventions | Polyphenon E, erlotinib hydrochloride, Erlotinib placebo |
| Enrollment | 17 |
| Start date | May 1, 2004 |
| Primary completion | Jul 1, 2006 |
| Completion | Jul 1, 2006 |
| First posted | Aug 5, 2004 |
| Last update posted | Jul 31, 2020 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: